-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The phase III checkpeer -227 trial compared the safety and efficacy of nivolumab + ipilimumab (nivo+ipi) combined immunotherapy and chemotherapy.
These patients have not received systemic treatment before, and have no sensitive EGFR mutations or known ALK changes.
.
The three-year overall survival (OS) data of this trial was announced at the 2020 ASCO annual meeting, showing that about one-third of PD-L1-positive and PD-L1-negative patients are still alive after receiving nivo+ipi for 3 years
The phase III checkpeer -227 trial compared the safety and efficacy of nivolumab + ipilimumab (nivo+ipi) combined immunotherapy and chemotherapy.
These patients have not received systemic treatment before, and have no sensitive EGFR mutations or known ALK changes.
.
At the 2021 ASCO annual meeting
The results found that in the primary endpoint population, the experiment continued to show that the survival rate of the ipi+nivo group was improved, and the overall risk ratio increased slightly (0.
76) , which means that the 4- year survival rate of patients receiving chemotherapy increased from 18% to 29%
.
The results have nothing to do with PD-L1 expression and histology
The results found that in the primary endpoint population, the experiment continued to show that the survival rate of the ipi+nivo ipi+nivo group increased, and the survival rate of the group with a slightly increased overall hazard ratio increased, and the overall hazard ratio increased slightly (0.
The updated results actually continue to support the use of nivo+ipi as a good choice for first-line treatment of patients with advanced NSCLC
During the discussion, Dr.
Dingemans repeatedly emphasized the need to continue to search for new biomarkers (except for PD-L1 expression status)
.
Although immunotherapy has become the standard treatment for wild-type metastatic NSCLC, whether it is monotherapy or combination chemotherapy, not all patients can benefit from immunotherapy
It is necessary to continue to search for new biomarkers (except PD-L1 expression status).
It is necessary to continue to search for new biomarkers (except PD-L1 expression status) although immunotherapy has become the standard treatment for wild-type metastatic NSCLC, regardless of Whether it is monotherapy or combination chemotherapy, not all patients can benefit from immunotherapy.
Although immunotherapy has become the standard treatment for wild-type metastatic NSCLC, whether it is monotherapy or combination chemotherapy, not all patients can benefit from immunotherapy.
Benefits from treatment leave a message here
